All In Biotech

Drug Trial Radar · NCT03400033

Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-Three-times Weekly Dosing in Dialysis (ASCEND-TD)

A Phase 3 Randomized, Double-blind, Active-controlled, Parallel-group, Multi-center Study in Hemodialysis Participants With Anemia of Chronic Kidney Disease to Evaluate the Efficacy, Safety and Pharmacokinetics of Three-times Weekly Dosing of Daprodustat Compared to Recombinant Human Erythropoietin, Following a Switch From Recombinant Human Erythropoietin or Its Analogs

Last checked: Nov 19, 2026Latest source record: Jul 12, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 407 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

407

Actual

Start

Sep 5, 2018

Primary completion

Jun 19, 2020

Study completion Jun 19, 2020

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Jan 17, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase 3 study in hemodialysis-dependent subjects with anemia will evaluate the efficacy and safety of daprodustat administered three-times weekly compared to epoetin alfa, the current standard of care. This study includes a 4 week Screening Period, a 52 week Treatment Period and a 4 to 6 week follow-up period. Each subject will remain in the study for up to 62 weeks. Approximately 402 subjects will be randomized to receive either daprodustat three times weekly or epoetin alfa three-times weekly or once weekly, depending on dose level.

Conditions

  • Anaemia

Interventions

  • Daprodustat tabletsDrug

    Round, biconvex, white, film-coated tablet in unit dose strengths 2 and 4 milligrams (7 millimeter tablets), 6, 8 and 10 milligrams (9 millimeter tablets) administered by the oral route.

  • Matching placebo tabletsDrug

    Matching placebo to daprodustat tablets supplied as round, biconvex, white, film-coated tablet in unit dose strengths 2 and 4 milligrams (7 millimeter tablets), 6, 8 and 10 milligrams (9 millimeter tablets) administered by the oral route.

  • Epoetin alfa vialsDrug

    Single-dose, preservative-free vials in unit dose strengths of 2000, 3000, 4000 and 10,000 Units/milliliter administered by the IV route.

  • Saline vials or bagsDrug

    0.9% sodium chloride saline vials or bags administered by the IV route.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Change From Baseline in Hemoglobin Levels Over the Evaluation Period (Week 28 to Week 52)Time frame: Baseline (Pre-dose on Day 1) and evaluation period (Week 28 to Week 52)

Locations

91 sites in 13 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Mesa, Arizona

  • GSK Investigational Site

    Fresno, California

  • GSK Investigational Site

    Los Angeles, California

  • GSK Investigational Site

    Paramount, California

  • GSK Investigational Site

    Middlebury, Connecticut

  • GSK Investigational Site

    Hollywood, Florida

  • GSK Investigational Site

    Miami, Florida

  • GSK Investigational Site

    Tampa, Florida

  • GSK Investigational Site

    Macon, Georgia

  • GSK Investigational Site

    Meridian, Idaho

  • GSK Investigational Site

    Pittsfield, Massachusetts

  • GSK Investigational Site

    Kansas City, Missouri

  • GSK Investigational Site

    St Louis, Missouri

  • GSK Investigational Site

    Albuquerque, New Mexico

  • GSK Investigational Site

    College Point, New York

  • GSK Investigational Site

    Winston-Salem, North Carolina

  • GSK Investigational Site

    Oklahoma City, Oklahoma

  • GSK Investigational Site

    Houston, Texas

  • GSK Investigational Site

    Houston, Texas

  • GSK Investigational Site

    Lufkin, Texas

  • GSK Investigational Site

    Alexandria, Virginia

  • GSK Investigational Site

    Hampton, Virginia

  • GSK Investigational Site

    Norfolk, Virginia

  • GSK Investigational Site

    Mar del Plata, Buenos Aires, Argentina

  • GSK Investigational Site

    Pergamino, Buenos Aires, Argentina

  • GSK Investigational Site

    Sarandí, Buenos Aires, Argentina

  • GSK Investigational Site

    Rosario, Santa Fe Province, Argentina

  • GSK Investigational Site

    Heidelberg, Victoria, Australia

  • GSK Investigational Site

    Parkville, Victoria, Australia

  • GSK Investigational Site

    Belo Horizonte, Minas Gerais, Brazil

  • GSK Investigational Site

    São Paulo, Brazil

  • GSK Investigational Site

    Salvador, Estado de Bahia, Brazil

  • GSK Investigational Site

    Curitiba, Paraná, Brazil

  • GSK Investigational Site

    Passo Fundo, Rio Grande do Sul, Brazil

  • GSK Investigational Site

    Porto Alegre, Rio Grande do Sul, Brazil

  • GSK Investigational Site

    São José do Rio Preto, São Paulo, Brazil

  • GSK Investigational Site

    Oshawa, Ontario, Canada

  • GSK Investigational Site

    Bayonne, France

  • GSK Investigational Site

    Epagny Metz-Tessy, France

  • GSK Investigational Site

    Le Mans, France

Showing 40 of 91 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.